Table 1.
Patient and clinicopathological characteristics of 100 patients treated with radical prostatectomy at the University Hospital Frankfurt between 01/2018 and 03/2021, with data available for both PAD-test and early continence status. All values are median (IQR) or frequencies (%).
| Study Cohort, (n = 100) |
|
|---|---|
| Age in years, Median (IQR) |
65 (58, 69) |
| PSA in mg/mL, Median (IQR) |
8 (6, 12) |
| Body Mass Index in kg/m2, Median (IQR) |
26.1 (24.3, 29.9) |
| International Prostate Symptom Score, Median (IQR) |
6.5 (3, 9) |
| Body Mass Index grouped in kg/m2, n (%) |
|
| ≤25 | 33 (34%) |
| 25–30 | 40 (41%) |
| ≥30 | 25 (26%) |
| D’Amico risk classification, n (%) |
|
| low | 13 (13%) |
| intermediate | 57 (57%) |
| high | 30 (30%) |
| Surgical approach, n (%) |
|
| robotic-assisted RP | 74 (74%) |
| open RP | 26 (26%) |
| Operation time in min, Median (IQR) |
218 (189, 252) |
| Prostate volume in cm3, Median (IQR) |
40 (30, 50) |
| pT-stage, n (%) |
|
| pT2a | 6 (6.0%) |
| pT2b | 1 (1.0%) |
| pT2c | 48 (48%) |
| pT3a | 33 (33%) |
| pT3b | 10 (10%) |
| pT4 | 2 (2.0%) |
| Extraprostatic extension of tumor, n (%) |
|
| no | 55 (55%) |
| yes | 45 (45%) |
| pN-stage, n (%) |
|
| pN0 | 85 (85%) |
| pN1 | 4 (4.0%) |
| pNx | 11 (11%) |
| cM-stage, n (%) |
|
| M0 | 96 (96%) |
| M1 | 4 (4.0%) |
| Gleason Grade Group RP-specimen, n (%) |
|
| I | 9 (9%) |
| II | 53 (54%) |
| III | 19 (19%) |
| IV | 4 (4%) |
| V | 13 (13%) |
| Nerve sparing, n (%) |
|
| none | 7 (7%) |
| uni/bilateral | 93 (93%) |
| Positive surgical margin, n (%) |
|
| R0 | 63 (63%) |
| R1 | 34 (34%) |
| Rx | 3 (3%) |